Tanja Badovinac-Črnjević

Author

Also Known As

Badovinac-Črnjević, Tanja, St Louis, Jessica, T. Badovinac-Crnjevic, Tanja Badovinac-Crnjevic, Tanja Badovinac-Crnjević, Tanja Badovinac-Črnjević

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital Harvard University Sunnybrook Health Science Centre University Hospital Centre Zagreb Wilhelminen Hospital

About

Tanja Badovinac-Črnjević is an author at Massachusetts General Hospital specializing in breast cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.6K
2	Public Health	2	2	993
3	Global Health	2	2	993
4	Health Sciences	1	1	504
5	Cell Biology	1	1	11

Tanja Badovinac-Črnjević

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, The Lancet Oncology Breast OncologyMedicineClinical TrialsBreast CancerPharmacotherapy	2017	504
Challenges to effective cancer control in China, India, and Russia Paul E. Goss, Kathrin Strasser‐Weippl, Brittany Bychkovsky, The Lancet Oncology MedicineGlobal HealthCancer ManagementCancer PreventionBreast Cancer	2014	497
Planning cancer control in Latin America and the Caribbean Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević, The Lancet Oncology Preventive MedicineMedicineGlobal HealthEpidemiology Of CancerCancer Prevention	2013	496
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study Dennis C. Sgroi, Judy‐Anne W. Chapman, Tanja Badovinac-Črnjević, Breast Cancer Research	2016	71
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial Paul E. Goss, Dawn L. Hershman, Angela M. Cheung, The Lancet Oncology Breast OncologyBone HealthEarly Breast CancerMedicineBone Mineral Density	2014	52
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer Karina J. Matissek, Maristela L. Onozato, Sheng Sun, Cancer Discovery	2017	44
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27 Kathrin Strasser‐Weippl, Michaela J. Higgins, Judith‐Anne W. Chapman, JNCI Journal of the National Cancer Institute	2018	23
Experimental and calculation procedures for molecular lipophilicity: A comparative study for 3,3'-(2-methoxybenzylidene)bis(4-hydroxycoumarin) Marica Medič-Šarić, Ana Mornar, Tanja Badovinac-Črnjević, Hrčak Portal of scientific journals of Croatia (University Computing Centre)	2004	17
Significance of epidermal growth factor receptor expression in breast cancer Tanja Badovinac-Črnjević, Jasminka Jakić‐Razumović, Paula Podolski, Medical Oncology Breast OncologyOncologyMedicineCancer GrowthPathology	2010	11

Page 1